For the convenience of treatnt, Shen Guohua was transferred from Modu Ruijin Hospital to Sanbo Research Institute, with Dr. Li accompanying him to the institute.
Five days later, treatnt began.
Shen Guohua had already signed the 12-page inford consent form, with three pages specifically explaining the experintal nature of the new vector. His eyes were calm, even with a peculiar sense of relief, at least he was fighting to live, rather than passively waiting for death; for a terminal patient, hope, even a sliver, is extrely important.
Yang Ping had Dr. Li treat Shen Guohua, as he was his patient. In the ward, everyone was on high alert.
"Mr. Shen, we are about to start," Dr. Li said, "The process is just like a normal infusion, about twenty minutes. After that, you may have fever, chills, and muscle aches, which are side effects of the dication, and we have experience dealing with these side effects; they are controllable."
Shen Guohua nodded and closed his eyes, the drug fluid entered his blood vessels through the venous indwelling needle.
Treatnt for twenty minutes, closely watched for seventy-two hours. These seventy-two hours were a test of life and death for Shen Guohua, a test of technology for Yang Ping’s team, and K Therapy began challenging the "king of cancer."
...
Around the world, the first batch of trainees who graduated from the Sanbo training program began their first independent treatnt after returning to their countries.
At the Brazil Sao Paulo Tumor Center, Dr. Carlos encountered an unexpected problem.
His first patient was a fifty-six-year-old woman with late-stage breast cancer, the tumor had already tastasized to her bones and lungs. According to the standard procedure, Carlos conducted an adenovirus antibody screening before treatnt, revealing the patient had moderate or higher antibody positivity to types 5, 26, and 35.
"This ans all existing vectors may not be effective," Carlos explained to the patient’s family. "We can try using immunosuppressive agents to pre-treat and lower the antibody levels before treatnt, but this will increase the risk of infection."
The patient’s daughter, a lawyer in her thirties, asked a pointed question: "Doctor, this therapy has not yet been officially approved in Brazil, it’s just a clinical trial. If my mother’s treatnt is ineffective, can we sue the hospital or the Chinese technology provider?
Carlos froze. In the training program, they learned about techniques, operations, and handling complications, but no one taught them how to deal with this kind of distrust, which was not a technical issue but a sociological one.
"The inford consent form signed before treatnt already explained all the risks," he tried to maintain professionalism, "but as a doctor, I must tell you the truth: all treatnts have uncertainties, especially experintal treatnts with innovative therapy."
Ultimately, the family decided to forgo treatnt, hoping to wait for a more mature plan.
Carlos watched the patient being wheeled out of the consultation room, feeling a mixture of emotions. In the training program, they discussed how to save more people; in reality, the first hurdle was trust.
The sa issue appeared in a different form in India Mumbai.
Dr. Rajiv’s first patient was a late-stage colorectal cancer male from a poor family. According to the inclusive frawork’s tiered pricing, the patient’s out-of-pocket expense was about $3,000—a astronomical sum for a rural Indian family.
"Doctor, we can only raise this money by selling our land and everything valuable," the patient’s son said, "but if we spend so much money and my father still passes away, my younger siblings will be left with nothing."
Rajiv couldn’t answer this question. The training program taught him dicine, but it didn’t teach him how to asure the value of life, how to advise a family to take on the risk of treatnt when it could plunge them into poverty.
He called his instructor, Song Zimo, at the training program in Nandu. On the other end of the line, Song Zimo was silent for a long ti, then said, "Dr. Rajiv, this is the most realistic issue facing the global promotion of the inclusive frawork. What we can do is ensure the efficiency and safety data of the treatnt is truthful and transparent, allowing the patient and their family to make inford choices. As for the choice itself, that’s a right and fate that belongs to each family. We can only treat the disease, not fate."
After hanging up, Rajiv looked at the dozens of patients lined up outside the consultation room. They all had the sa desire for life in their eyes. And the K Therapy in his hands might be hope for so, a heavy burden for others.
We can only treat the disease, not fate.
Rajiv silently recited this phrase in his heart.
In the end, the patient’s family gave up treatnt—they didn’t think it was worth it.
...
Ten days after the Zurich eting, the European Commission Health Departnt issued an eighty-page "Interim Guidelines on Cross-border Transfer of Data for Specific Breakthrough dical Technologies."
This docunt did not and the GDPR, but created a special channel: for innovative therapies that, after rigorous evaluation, can significantly improve the survival of patients with no available treatnts, cross-border data transfers are permitted if the following conditions are t:
The data recipient must pass the European Union’s data security certification;
Transferred data is limited to the minimum necessary for clinical decision making;
A joint supervisory committee is established, with the European side having real-ti monitoring of data access and a veto power;
All data must have complete mirror storage within the European Union;
Re-evaluation after three years to decide whether to continue or modify based on technological developnts.
This was a compromise, but also a breakthrough," Lady Windsor said over the phone to Huang Jiacai, "Next, it will be up to you to et those stringent certification requirents."
User Comments
0 comments from readers